Cost-Effectiveness Analysis of Salmeterol/Fluticasone Propionate 50/100??g vs Fluticasone Propionate 100??g in Adults and Adolescents with Asthma III: Results

Johansson, Gunnar; Price, Martin; Sondhi, Seema

doi:10.2165/00019053-199916002-00003

Cited by 25 publications

(16 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the higher drug costs for SFC, the cost per successfully treated week was found to be lower for SFC than FP alone in all studies. The ICERs reported in three studies were estimated to be $20.91, $30.12, and $26.04, respectively 38,40,41. Similarly, the result of a prospective economic analysis comparing SFC 50/250 mg twice daily versus BUD 800 mg twice daily in adults and adolescents with asthma suggested that SFC was more cost-effective than BUD alone.…”

Section: Resultsmentioning

confidence: 98%

See 1 more Smart Citation

A systematic review of economic evaluations of therapy in asthma

Bahadori

Quon²,

Doyle‐Waters³

et al. 2010

JAA

View full text Add to dashboard Cite

Background:Asthma’s cost-effectiveness is a major consideration in the evaluation of its treatment options. Our objective was to perform a systematic review of the cost-effectiveness of asthma medications.Methods:We performed a systematic search of MEDLINE, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, OHE-HEED, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Controlled Trials, Health Technology Assessments Database, NHS Economic Evaluation Database, and Web of Science and reviewed references from key articles between 1990 and Jan 2008.Results:A total of 49 RCTs met the inclusion criteria. Maintenance therapy with inhaled corticosteroids was found to be very cost-effective and in uncontrolled asthmatics patients currently being treated with ICS, the combination of an ICS/LABA represents a safe, cost-effective treatment. The simplified strategy using budesonide and formoterol for maintenance and reliever therapy was also found to be as cost-effective as salmeterol/fluticasone plus salbutamol. Omalizumab was found to be cost-effective. An important caveat with regard to the published literature is the relatively high proportion of economic evaluations which are funded by the manufacturers of specific drug treatments.Conclusion:Future studies should be completed independent of industry support and ensure that the comparator arms within studies should include dosages of drugs that are equivalent.

show abstract

Section: Resultsmentioning

confidence: 98%

“…In five studies the cost-effectiveness of SFC 50/100 μg with fluticasone propionate 100 μg was compared 15,38–41. Despite the higher drug costs for SFC, the cost per successfully treated week was found to be lower for SFC than FP alone in all studies.…”

Section: Resultsmentioning

confidence: 99%

A systematic review of economic evaluations of therapy in asthma

Bahadori

Quon²,

Doyle‐Waters³

et al. 2010

JAA

View full text Add to dashboard Cite

show abstract

“…A total of 15 226,[252][253][254][255][256][257][258][259][260][261][262][263][264][265] published full-text studies were judged as full economic evaluations and met our inclusion criteria and involved adults with asthma. All of the 15 studies were published after 1994.…”

Section: Summary Of the Included Cost-effectiveness Studiesmentioning

confidence: 99%

“…There is also duplicate publication in some of the studies comparing FP with FP/SAL from the Swedish health system perspective (with the analyses by Pieters and colleagues 262 and Palmqvist and colleagues 261 and Johansson and colleagues 257 also appearing in the paper by Lundbäck and colleagues 259 ). The wide variation in the comparators in different studies, in terms of both the drug types and daily dosages, is such that few meaningful comparisons can be made between studies.…”

Section: Study Types and Settingsmentioning

confidence: 99%

“…In summary, although there are a number of economic evaluations that could be relevant to the current decision problem, the very wide variations in health system settings and study perspectives, drug comparators, dose levels, outcome measures and model structures or trial designs and durations, makes the evidence base relatively uninformative. 268 Palmqvist et al, 261 Pieters et al 262 and Johansson et al 257 involve duplicate publication of the cost-effectiveness comparisons reported in Lundbäck et al A summary of the published economics evaluation studies in adults is given in Table 71.…”

Section: Study Types and Settingsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Shepherd¹,

Rogers²,

Anderson³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These sugges...

show abstract